# IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease

> **NCT04136028** · EARLY_PHASE1 · COMPLETED · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 13 (estimated)

## Conditions studied

- Chronic Granulomatous Disease

## Interventions

- **DRUG:** Kineret

## Key facts

- **NCT ID:** NCT04136028
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-25
- **Primary completion:** 2019-01-16
- **Final completion:** 2020-01
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2020-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04136028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04136028, "IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04136028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*